

## Clinical Need

Ophthalmologists need a way to achieve sustained dilation of Schlemm's Canal and distal collector channels in order to increase aqueous humor outflow.

## Background

### Glaucoma Induced Vision Loss is Irreversible


 90% of vision loss is avoidable

 12 Million people suffer from Glaucoma in India alone

**2** Leading cause of blindness


### Our Target: Schlemm's Canal

Restoring eye's natural drainage system to reduce intraocular pressure



## Current Surgical Solutions Shortcomings

### Inadequacies of Contemporary Glaucoma Treatment



Ineffective in highly pigmented eyes




Invasive and prone to scarring



Unrepeatable and destroys tissue

## Solution Concept: Hydrogel Injection




 Direct dilation of distal collector channels

 Preserves natural anatomy

 Potential for unlimited repeatability

 No additional operative difficulty

 Likely lower price than implants

 Existing evidence of viscoelastic dilation

## Clinical Value Proposition

### Establishing A Means of Sustained Dilation Will...

(1) Increase longevity of IOP reduction

(2) Decrease the number of medications patients require

(3) Decrease the number of total operations for glaucoma

## Economic Value Proposition

### Glaucoma Intervention Market in the United States

~132,000 procedures | \$5,450 avg cost of MIGS | 46% of Glaucoma market is MIGS → **\$331M**

### Glaucoma Intervention Market in India

~750,000 procedures | \$240 avg cost of MIGS | 46% of Glaucoma market is MIGS → **\$83M**

## Milestones

- 1) Concept De-Risking**  
Completed benchtop testing determining ideal curability of gel
- 2) Regulatory Classification**  
Class III PMA using Hydrus Microstent as Reference device
- 3) Applicator Prototyped**  
Mechanical syringe applicator optimizes surgeon control